Adaptimmune Therapeutics PLC (NASDAQ:ADAP) posted its earnings results on Thursday. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.24), Morningstar.com reports. Adaptimmune Therapeutics PLC had a negative return on equity of 41.40% and a negative net margin of 550.22%.
Shares of Adaptimmune Therapeutics PLC (ADAP) traded up 1.12% during trading on Thursday, hitting $5.40. 108,648 shares of the stock traded hands. Adaptimmune Therapeutics PLC has a 52 week low of $3.76 and a 52 week high of $8.89. The company’s market capitalization is $382.29 million.
A number of analysts recently issued reports on the company. ValuEngine raised Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 20th. Zacks Investment Research cut Adaptimmune Therapeutics PLC from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. BidaskClub raised Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a research note on Sunday, July 16th. Finally, Cowen and Company reissued a “buy” rating on shares of Adaptimmune Therapeutics PLC in a research note on Tuesday, June 6th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. Adaptimmune Therapeutics PLC has a consensus rating of “Hold” and an average price target of $12.08.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://stocknewstimes.com/2017/08/03/adaptimmune-therapeutics-plc-nasdaqadap-announces-earnings-results-hits-expectations.html.
Several large investors have recently added to or reduced their stakes in the stock. Alps Advisors Inc. boosted its stake in Adaptimmune Therapeutics PLC by 4.9% in the second quarter. Alps Advisors Inc. now owns 63,892 shares of the biotechnology company’s stock worth $287,000 after buying an additional 2,996 shares during the period. Creative Planning boosted its stake in Adaptimmune Therapeutics PLC by 32.8% in the first quarter. Creative Planning now owns 40,500 shares of the biotechnology company’s stock worth $223,000 after buying an additional 10,000 shares during the period. Raymond James Financial Services Advisors Inc. acquired a new stake in Adaptimmune Therapeutics PLC during the first quarter worth about $120,000. KCG Holdings Inc. acquired a new stake in Adaptimmune Therapeutics PLC during the first quarter worth about $133,000. Finally, Monashee Investment Management LLC acquired a new stake in Adaptimmune Therapeutics PLC during the first quarter worth about $138,000. Hedge funds and other institutional investors own 56.16% of the company’s stock.
Adaptimmune Therapeutics PLC Company Profile
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.
